Author Guidelines

Sections

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details

1. SUBMISSION

Thank you for your interest in Veterinary and Comparative Oncology. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting on symposium.

Please note that we also follow the recommendations set out by the International Committee of Medical Journal Editors (ICJME). For more information, visit their website at http://www.icmje.org/journals-following-the-icmje-recommendations/.

New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/VCO. Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal. You may check the status of your submission at any time by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

The submission system will prompt you to use an ORCiD (a unique author identifier) to help distinguish your work from that of other researchers. Click here to find out more.

Click here for more details on how to use Research Exchange.

For help with submissions, please contact: [email protected]

We look forward to your submission.

Data Protection and Privacy

By submitting a manuscript to, or reviewing for, this publication, your name, email address, institutional affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

Preprint Policy

Veterinary and Comparative Oncology will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.

2. AIMS AND SCOPE

Veterinary and Comparative Oncology (VCO) is an international, peer-reviewed journal integrating clinical and scientific information from a variety of related disciplines and from worldwide sources for all veterinary oncologists and cancer researchers concerned with aetiology, diagnosis and clinical course of cancer in domestic animals and its prevention. With the ultimate aim of diminishing suffering from cancer, the journal supports the transfer of knowledge in all aspects of veterinary oncology, from the application of new laboratory technology to cancer prevention, early detection, diagnosis and therapy. In addition to original articles, the journal publishes solicited editorials, review articles, commentary, correspondence and abstracts from the published literature. Accordingly, studies describing laboratory work performed exclusively in purpose-bred domestic animals (e.g. dogs, cats, horses) will not be considered. Current editorial policy has been to administratively decline to publish case reports or small retrospective case series unless the information contained therein will change the standard of care for therapy, diagnosis, or investigation of the tumour in question. From time to time, VCO may publish themed issues to cover areas of importance or debate, e.g. the management of a specific tumour type, or tumour-associated condition.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Veterinary and Comparative Oncology publishes a number of different article types including:

Pilot Studies

Manuscripts entitled “pilot studies” or “preliminary studies” submitted to Veterinary and Comparative Oncology must include the following information: a statement detailing how the data will be used in subsequent studies; OR a power calculation for the follow-up study; OR confirmation that a follow-up study is forthcoming. Submissions which do not include any of this information will be rejected from further consideration.

4. PREPARING YOUR SUBMISSION

Manuscripts must be submitted as a Word or rtf file and should be written in English. Manuscripts should be double-spaced with continuous line numbering. The manuscript should be submitted in separate files: title page; main text file; figures.

Main Text File

Should your manuscript reach revision stage, figures and tables must be provided as separate files. The main manuscript file can be submitted in Microsoft Word (.doc or .docx) or LaTex (.tex) format.

If submitting your manuscript file in LaTex format via Research Exchange, select the file designation “Main Document – LaTeX .tex File” on upload. When submitting a Latex Main Document, you must also provide a PDF version of the manuscript for Peer Review. Please upload this file as “Main Document - LaTeX PDF.” All supporting files that are referred to in the Latex Main Document should be uploaded as a “LaTeX Supplementary File.”

Your main document file should include:

• A short informative title containing the major key words. The title should not contain abbreviations
• Abstract 
• 3-6 keywords;
• Main body: formatted as introduction, methods, results, discussion,
• References;
• Tables (each table complete with title and footnotes);

• Figures: Figure legends must be added beneath each individual image during upload AND as a complete list in the text. Figures should be numbered in the order that they are cited in the text, and presented in that order after the text of the paper.

Title page

The title page should contain:
(i) a short informative title that contains the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
(ii) a short running title of less than 40 characters;
(iii) Full names (First, Middle, and Last) should be provided for all authors

 (iv) Authors should include the complete affiliation addresses where the work was carried out in the manuscript. At minimum, authors should include the institution name and country, but a complete affiliation also includes department name and institution city. The institution postal code is optional.
(v) acknowledgements.

The present address of any author, if different from that where the work was carried out, should be supplied in a footnote.

Authorship

Please refer to the journal’s authorship policy the Editorial Policies and Ethical Considerations section for details on eligibility for author listing.

The use of Artificial Intelligence

Artificial Intelligence Generated Content (AIGC) tools—such as ChatGPT and others based on large language models (LLMs)—cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for research design, which is a generally held requirement of authorship (as discussed in the previous section), nor do they have legal standing or the ability to hold or assign copyright. Therefore—in accordance with COPE’s position statement on AI tools—these tools cannot fulfill the role of, nor be listed as, an author of an article. If an author has used this kind of tool to develop any portion of a manuscript, its use must be described, transparently and in detail, in the Methods or Acknowledgements section. The author is fully responsible for the accuracy of any information provided by the tool and for correctly referencing any supporting work on which that information depends. Tools that are used to improve spelling, grammar, and general editing are not included in the scope of these guidelines. The final decision about whether use of an AIGC tool is appropriate or permissible in the circumstances of a submitted manuscript or a published article lies with the journal’s editor or other party responsible for the publication’s editorial policy.

Acknowledgements

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. See section on Authorship for more detail. Authors should list all funding sources or indicate if no financial support has been provided. Material support should also be mentioned. Thanks to anonymous reviewers are not appropriate. 

Conflict of Interest Statement

You will be asked to provide a conflict of interest statement during the submission process. See the section ‘Conflict of Interest’ in the Editorial Policies and Ethical Considerations section for details on what to include in this section. Please ensure you liaise with all co-authors to confirm agreement with the final statement. The Conflict of Interest statement should be included within the main text file of your submission.

Main Text

As papers are double-blind peer reviewed the main text file should not include any information that might identify the authors.

The main text file should be presented in the following order: (i) title, disclaimers, source(s) of support, word count, number of figures and tables, conflict of interest declaration, (ii) abstract and key words, (iii) introduction, (iv) methods, (v) results (vi) discussion, (vii) references, (viii) tables, (ix) illustrations (figures). Figures and supporting information should be supplied as separate files.

For further guidance on the content and style of the introduction, materials and methods, results and discussion, please follow the International Committee of Medical Journal Editors (ICJME) Uniform Requirements for Manuscripts Submitted to Biomedical Journals: http://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html

Editorials, Short Communications and Letters to the Editor should be written in continuous prose with appropriate references, figures and tables as required.

Abstract

Please provide an abstract of no more than 250 words. Subheadings are not necessary.

Keywords

Please provide 3-6 keywords and list them in alphabetical order. Keywords should not appear in the title of the article. Keywords should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list at https://www.nlm.nih.gov/mesh/.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. For more information about AMA reference style please consult this guide, or the AMA Manual of Style website.

Sample references follow:

Journal Article (1-6 authors)
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551. 

Journal Article (more than 6 authors)
2. Barrett LE, Skorupski K, Brown DC, et al. Outcome following treatment of feline gastrointestinal mast cell tumours. Vet Comp Oncol 2018;16(2):188-193. 

Entire Book
3. McKenzie BC. Medicine and the Internet: Introducing Online Resources and Terminology. 2^nd ed. New York, NY: Oxford University Press; 1997. 

Book Chapter
4. Guyton JL, Crockarell JR. Fractures of acetabulum and pelvis. In: Canale ST, ed. Campbell’s Operative Orthopaedics. 10^th ed. Philadelphia, PA: Mosby, Inc; 2003:2939-2984. 

Internet Document
5. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf Accessed March 3, 2003

Tables

Tables should be self-contained and complement, but not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Preparing Figures

Although we encourage authors to send us the highest-quality figures possible, for peer-review purposes we are happy to accept a wide variety of formats, sizes, and resolutions.

Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Colour figures: Figures submitted in colour may be reproduced in colour free of charge.

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text. Supporting Information

Supporting Information

Supporting information is information that is not essential to the article but that provides greater depth and background. It is hosted online, and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information.

Note, if data, scripts or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following links provide general advice on formatting and style.

• Abbreviations:In general, terms should not be abbreviated unless they are used repeatedly, and the abbreviation is helpful to the reader. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
• Units of measurement:Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at http://www.bipm.fr for more information about SI units.
• Trade Names:Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

Article Preparation Support 

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance

The acceptance criteria for all papers is the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are double-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements. Wiley’s policy on confidentiality of the review process is available here.

Revised manuscripts must be uploaded within one month of authors being notified of conditional acceptance pending satisfactory revision. Locate your manuscript under ‘Manuscripts with Decisions’ and click on ‘Submit a Revision’ to submit your revised manuscript. Please include a POINT BY POINT response to reviewers as part of your revised submission. In addition, please upload a revised version of your manuscript with changes clearly highlighted. Please remember to delete any old files uploaded when you upload your revised manuscript.

Refer and Transfer Program

Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant.

Data Sharing and Data Accessibility

Veterinary and Comparative Oncology recognizes the many benefits of archiving research data. The journal expects you to archive all the data from which your published results are derived in a public repository. The repository that you choose should offer you guaranteed preservation (see the registry of research data repositories at https://www.re3data.org/) and should help you make it findable, accessible, interoperable, and re-useable, according to FAIR Data Principles (https://www.force11.org/group/fairgroup/fairprinciples). All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. If you cannot share the data described in your manuscript, for example for legal or ethical reasons, or do not intend to share the data then you must provide the appropriate data availability statement. Veterinary and Comparative Oncology notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage you to share data in ways that are as open as possible (but that can be as closed as necessary). Sample statements are available here. If published, all statements will be placed in the heading of your manuscript.

Data Citation

Please also cite the data you have shared, like you would cite other sources that your article refers to, in your references section. You should follow the format for your data citations laid out in the Joint Declaration of Data Citation Principles, https://www.force11.org/datacitationprinciples:

[dataset] Authors; Year; Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI)

Human Studies and Subjects

For manuscripts reporting medical studies involving human participants, we require a statement identifying the ethics committee that approved the study, and that the study conforms to recognized standards, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

Images and information from individual participants will only be published where the authors have obtained the individual’s free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher, however in signing the author license to publish authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, and the name of the body giving approval, must be included in the Methods section of the manuscript. We encourage authors to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines and regulations for the care and use of laboratory animals:

• US authors should cite compliance with the US National Research Council’s Guide for the Care and Use of Laboratory Animals, the US Public Health Service’s Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trial Registration

We require that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for this.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. We encourage authors to adhere to the following research reporting standards.

• PETSORT
• CONSORT
  • SPIRIT
  • PRISMA
  • PRISMA-P
  • STROBE
  • CARE
  • COREQ
  • STARDand TRIPOD
  • CHEERS
  • The EQUATOR Network
  • Future of Research Communications and e-Scholarship (FORCE11)
  • ARRIVE guidelines
  • National Research Council's Institute for Laboratory Animal Research guidelines: the Gold Standard Publication Checklist from Hooijmans and colleagues
  • Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website; Biosharing website
  • REFLECT statement

Standardization of pathologic tumor assessment

If mitotic figures are enumerated in a neoplasm, then the method used, microscope vs whole slide imaging (WSI) must be stated and the actual area counted must be reported in standard international units for area, mm². The correct term is mitotic count (not mitotic index). The area chosen needs to be defined as: hot spot (area with numerous mitotic figures), or random or haphazard or invasive front. Guidelines that detail how to perform MC and define mitotic figures, atypical mitotic figures and mitotic like figures are referenced and should be followed. The material and methods section should provide details like:

• Mitotic figures were counted with a microscope (or WSI) in an area with numerous mitotic figures (hot spot), the area was 2.37 mm² :10 contiguous 400X fields (FN 22 mm ocular), not overlapping, avoiding and/or skipping areas of the tumor that are cell-poor from hemorrhage, edema, necrosis, cysts, etc. For problematic samples e.g. sample size <2.37 mm², abundant necrosis or inflammation, describe how mitotic count was determined.
• Necrosis – describe method – histologic only (or gross and histological); optical estimate vs morphometry see vcgp.org Moore FM et al. Tumor Necrosis Guideline, version 1.1. Veterinary Cancer Guidelines and Protocols. http://vetcancerprotocols.org
• Lymphovascular invasion (LVI) –define if soft vs strict criteria were used; strict criteria preferred; see vcgp.org Moore FM et al. Lymphovascular Invasion Guideline, version 1.0. Veterinary Cancer Guidelines and Protocols. http://vetcancerprotocols.org
• For surgical margins- specify the method of inking used (in surgery or by the laboratory), sectioning (radial, tangential, bread-loaf or mixed), and how margins were assessed.

Species Names

Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, the scientific name should be used only.

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see http://varnomen.hgvs.org/, where examples of acceptable nomenclature are provided.

Nucleotide Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

DNA Data Bank of Japan (DDBJ) http://www.ddbj.nig.ac.jp

EMBL Nucleotide Sequence Submissions http://www.ebi.ac.uk

GenBank http://www.ncbi.nlm.nih.gov

Cross-Species Antibodies

Papers reporting the results of protein analysis (flow cytometry, immunohistochemistry, immunocytochemistry, immunoprecipitation) that utilize antibodies directed against a protein or epitope from another species (e.g. anti-human or anti-murine antibodies used to interrogate protein expression in a dog or cat) should provide appropriate validation of the specificity and cross-reactivity of the antibodies as described in Ramos-Vara et al (J Vet Diagn Invest 2008;20:93). Specifically, antibodies should demonstrate reactivity with the appropriate molecular weight antigen in western blots. Alternatively, citations demonstrating such validation must be provided.

Cell Line Authentication Statement

VCO strongly encourages authors to authenticate all cell lines used in the research submitted to the journal for uniqueness and species of origin. All original research submissions that include the use of cell lines must include a cell line authentication statement even if validation testing has not been conducted (i.e. a null statement). VCO requests that authors detail what authentication testing they have conducted, if any, in their authentication statement. If authentication testing has not been conducted, the reasons for this should be clearly stated in the authentication statement. This statement should be provided in the Materials and Methods section of your manuscript under the heading, ‘Cell Line Authentication Statement’.

Conflict of Interest

Veterinary and Comparative Oncology requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. The Conflict of Interest statement should be included within the main text file of your submission.

Veterinary and Comparative Oncology also requires disclosure of any conflict of interest from its reviewers. As Veterinary and Comparative Oncology is a member of COPE, we suggest you follow the guidelines for reviewers available at http://publicationethics.org/files/Ethical_guidelines_for_peer_reviewers_0.pdf.

Funding

Authors should list all funding sources or indicate if no financial support has been provided in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: http://www.crossref.org/fundingdata/registry.html.

Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1) Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;

2) Been involved in drafting the manuscript or revising it critically for important intellectual content;

3) Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and

4) Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Author Pronouns 

Authors may now include their personal pronouns in the author bylines of their published articles and on Wiley Online Library. Authors will never be required to include their pronouns; it will always be optional for the author. Authors can include their pronouns in their manuscript upon submission and can add, edit, or remove their pronouns at any stage upon request. Submitting/corresponding authors should never add, edit, or remove a coauthor’s pronouns without that coauthor’s consent. Where post-publication changes to pronouns are required, these can be made without a correction notice to the paper, following Wiley’s Name Change Policy to protect the author’s privacy. Terms which fall outside of the scope of personal pronouns, e.g. proper or improper nouns, are currently not supported. 

Author Name Changes

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

Correction to Authorship

In accordance with Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and the Committee on Publication Ethics’ guidance, Veterinary and Comparative Oncology will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the Request for Changes to a Journal Article Author List Form and contact either the journal’s editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author’s name; the relevant policy for that can be found in Wiley’s Best Practice Guidelines under “Author name changes after publication.”]

Additional authorship options

Joint first or senior authorship: In the case of joint first authorship a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

ORCID

As part of our commitment to supporting authors at every step of the publishing process, Veterinary and Comparative Oncology requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information.

Publication Ethics

Veterinary and Comparative Oncology is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at https://authorservices.wiley.com/ethics-guidelines/index.html

6. AUTHOR LICENSING

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal’s standard copyright agreement, or Open Access under the terms of a Creative Commons License.

General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under Open Access, please click here. (Note that certain funders mandate that a particular type of CC license has to be used; to check this please click here.)

Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

Open Access fees: If you choose to publish using Open Access you will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted article received in production

When your accepted article is received by Wiley’s production production team, you (corresponding authors) will receive an email asking you to login or register with Author Services. You will be asked to sign a publication licence at this point.

Proofs

Once your paper is typeset you will receive email notification of the URL from where to download a PDF typeset page proof, associated forms and full instructions on how to correct and return the file.

Please note that you are responsible for all statements made in your work, including changes made during the editorial process and thus you must check your proofs carefully. Note that proofs should be returned 48 hours from receipt of first proof.

Guidelines for Cover Submissions

If you would like to send suggestions for artwork related to your manuscript to be considered to appear on the cover of the journal, please follow these general guidelines.

Early View

The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Once your article is published on Early View no further changes to your article are possible. Your Early View article is fully citable and carries an online publication date and DOI for citations.

8. POST PUBLICATION

Access and sharing

When your article is published online:
• You receive an email alert (if requested).
• You can share your published article through social media.
• As the author, you retain free access (after accepting the Terms & Conditions of use, you can view your article).
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to your article.

Article Promotion Support 

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

9. EDITORIAL OFFICE CONTACT DETAILS

[email protected]

Author Guidelines updated 21st February 2024